Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
For research purposes only [email protected] +447449201766 Customer Support Shipping Policy Returns & Refunds Terms & Conditions Privacy Policy Contact Us Quick links Shop All FAQs My account View Cart Newsletter Join our mailing list for research updates, exclusive offers, and the latest news
[14] HA-KPV nanoparticles demonstrated superior mucosal outcomes compared to free KPV in both in vitro and in vivo ulcerative colitis models
Key Research Characteristics: Selective NNMT inhibition, supporting studies into NAD metabolism and methylation pathways Investigated in the context of obesity, metabolic dysfunction, and lipid accumulation models Cell-permeable small molecule with favourable in vitro profile Studied for potential effects on adipocyte differentiation and energy expenditure Specifications: Form: Lyophilised powder For research purposes only
In REDEFINE 1 (NEJM 2025, n=3,417, 68 weeks), cagrilintide monotherapy at 2.4 mg produced 11.8% mean body-weight reduction versus 2.3% with placebo
The peptide's anti-inflammatory properties prove particularly beneficial in the post-surgical period when excessive inflammation can impair healing and increase complication risk
AOD-9604: Does not cause receptor burnout Does not require washout periods Does not lose effectiveness due to continuous use Consistency, not cycling, aligns with how it was designed to work
US$ 20.62
US$ 24.09
US$ 26.63
US$ 21.70
US$ 21.31
US$ 28.54
US$ 20.21
US$ 29.18
